Abstract
Liposomal nucleic acid delivery is a preferred option for therapeutic settings. The cellular pattern recognition molecule DMBT1, secreted at high levels in various diseases, and synthetic mimics efficiently inhibit liposomal nucleic acid delivery to human cells. These findings may have relevance for therapeutic nucleic acid delivery strategies.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Binding Sites
-
Biomimetic Materials / chemical synthesis
-
Biomimetic Materials / chemistry
-
Biomimetic Materials / pharmacology*
-
Calcium-Binding Proteins
-
Cell Line
-
DNA-Binding Proteins
-
Dose-Response Relationship, Drug
-
Drug Delivery Systems
-
Humans
-
Liposomes / chemistry*
-
Liposomes / metabolism
-
Mice
-
Models, Molecular
-
Mucins / antagonists & inhibitors*
-
Mucins / metabolism
-
Nucleic Acids / chemical synthesis
-
Nucleic Acids / chemistry
-
Nucleic Acids / pharmacology*
-
Peptide Fragments / chemistry
-
Peptide Fragments / metabolism
-
Peptide Fragments / pharmacology*
-
Receptors, Cell Surface / antagonists & inhibitors*
-
Receptors, Cell Surface / metabolism
-
Recombinant Proteins / antagonists & inhibitors
-
Recombinant Proteins / metabolism
-
Structure-Activity Relationship
-
Tumor Suppressor Proteins
Substances
-
Calcium-Binding Proteins
-
DMBT1 protein, human
-
DNA-Binding Proteins
-
Dmbt1 protein, mouse
-
Liposomes
-
Mucins
-
Nucleic Acids
-
Peptide Fragments
-
Receptors, Cell Surface
-
Recombinant Proteins
-
Tumor Suppressor Proteins